logo
Plus   Neg
Share
Email

Monsanto Posts Higher Q2 Profit; Ups FY12 EPS View - Quick Facts

Monsanto Co. (MON) posted an improvement in its second-quarter net income attributable to the company to $1.21 billion from year-ago quarter's $1.02 billion, with quarterly earnings per share growing to $2.24 from $1.88 last year, helped by the strong performance of the seeds and traits business and the timing of an early U.S. season.

Earnings per share from ongoing business for the recent quarter were $2.28, higher than $1.87 in the comparable period. On average, 20 analysts polled by Thomson Reuters expected earnings per share of $2.12 for the quarter. Analysts' estimates typically exclude one-time items.

Net sales totaled $4.75 billion compared with $4.13 billion in the previous year, while 13 analysts estimated revenues of $4.53 billion for the quarter.

For fiscal 2012, the company currently sees earnings per share of $3.45 - $3.50 on a reported basis and $3.49 - $3.54 on an ongoing basis. Previously, the company estimated to achieve $3.39 - $3.44 of ongoing and as-reported earnings per share for fiscal 2012. Twenty-two analysts project earnings of $3.51 per share for the full year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
As Canada prepares to legalize marijuana nationwide later this year, a national survey by Statistics Canada has thrown up some interesting facts - including that legal marijuana is not a temptation for most Canadians. Regardless of cannabis use, 79 percent of Canadians surveyed said they would not be more likely to try or increase their cannabis consumption just because it is legalized. The Procter & Gamble Company (PG) reported third-quarter net earnings per share of $0.95, an increase of two percent versus the prior year. Net earnings from continuing operations declined 1% year-over-year to $2.54 billion. Core earnings per share increased four percent to $1.00. On average, 20 analysts... Consumer goods giant Procter & Gamble Co. announced Thursday that it has signed an agreement to acquire the Consumer Health business of German drug major Merck KGaA for a purchase price of approximately 3.4 billion euros. P&G expects to close the acquisition of Consumer Health business during the 2018/19 fiscal year, subject to customary closing conditions and regulatory clearances.
Follow RTT